Antitumoral effect of proliferation signal inhibitors;Effet antitumoral des inhibiteurs du signal de prolifération

Gastroenterologie Clinique et Biologique

Volumn 33, Issue SUPPL. 4, 2009, Pages

  Dumortier, J ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; EVEROLIMUS; FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; TEMSIROLIMUS; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER INHIBITION; CANCER INVASION; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MENTAL DISEASE; METASTASIS INHIBITION; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; NONHUMAN; POSTOPERATIVE PERIOD; PROTEIN FUNCTION; RECURRENT CANCER; SIGNAL TRANSDUCTION; SKIN TOXICITY; SOLID TUMOR; THROMBOCYTOPENIA;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER TRANSPLANTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS;

EID: 71149091855     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-8320(09)73164-1     Document Type: Article

References (37)

1. Buell J.F., Gross T.G., and Woodle E.S. Malignancy after transplantation. Transplantation 80 (2005) S254-S264
2. Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology 127 (2004) S268-S276
3. Duvoux C., Cherqui D., Delacroix I., Metreau J.M., Fagniez P.L., and Dhumeaux D. Upper respiratory and digestive tract malignancies after liver transplantation for alcoholic cirrhosis. Transplant Proc 28 (1996) 2883
4. Dumortier J., Guillaud O., Adham M., Boucaud C., Delafosse B., Bouffard Y., et al. Negative impact of de novo malignancies rather than alcohol relapse on survival after liver transplantation for alcoholic cirrhosis: a retrospective analysis of 305 patients in a single center. Am J Gastroenterol 102 (2007) 1032-1041
5. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
6. Neshat M.S., Mellinghoff I.K., Tran C., Stiles B., Thomas G., Petersen R., et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98 (2001) 10314-10319
7. Tee A.R., and Blenis J. mTOR, translational control and human disease. Semin Cell Dev Biol 16 (2005) 29-37
8. Mabuchi S., Altomare D.A., Connolly D.C., Klein-Szanto A., Litwin S., Hoelzle M.K., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 67 (2007) 2408-2413
9. Wu Q., Kiguchi K., Kawamoto T., Ajiki T., Traag J., Carbajal S., et al. Therapeutic effect of rapamycin on gallbladder cancer in a transgenic mouse model. Cancer Res 67 (2007) 3794-3800
10. Namba R., Young L.J., Abbey C.K., Kim L., Damonte P., Borowsky A.D., et al. Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin Cancer Res 12 (2006) 2613-2621
11. Majumder P.K., Febbo P.G., Bikoff R., Berger R., Xue Q., McMahon L.M., et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10 (2004) 594-601
12. Hosoi H., Dilling M.B., Shikata T., Liu L.N., Shu L., Ashmun R.A., et al. Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells. Cancer Res 59 (1999) 886-894
13. Beuvink I., Boulay A., Fumagalli S., Zilbermann F., Ruetz S., O'Reilly T., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 120 (2005) 747-759
14. Zhang D., Bar-Eli M., Meloche S., and Brodt P. Dual regulation of mmP-2 expression by the type 1 insulin-like growth factor receptor: the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals. J Biol Chem 279 (2004) 19683-19690
15. Lang S.A., Gaumann A., Koehl G.E., Seidel U., Bataille F., Klein D., et al. Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120 (2007) 1803-1810
16. Huber S., Bruns C.J., Schmid G., Hermann P.C., Conrad C., Niess H., et al. Inhibition of the mammalian target of rapamycin impedes lymphangiogenesis. Kidney Int 71 (2007) 771-777
17. Kobayashi S., Kishimoto T., Kamata S., Otsuka M., Miyazaki M., and Ishikura H. Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 98 (2007) 726-733
18. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
19. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
20. Ilan N., Mahooti S., and Madri J.A. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 111 (1998) 3621-3631 Pt 24
21. Yu Y., and Sato J.D. MAP kinases, phosphatidylinositol 3-kinase, and p70 S6 kinase mediate the mitogenic response of human endothelial cells to vascular endothelial growth factor. J Cell Physiol 178 (1999) 235-246
22. Guba M., von Breitenbuch P., Steinbauer M., Koehl G., Flegel S., Hornung M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8 (2002) 128-135
23. Bruns C.J., Koehl G.E., Guba M., Yezhelyev M., Steinbauer M., Seeliger H., et al. Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10 (2004) 2109-2119
24. Seeliger H., Guba M., Koehl G.E., Doenecke A., Steinbauer M., Bruns C.J., et al. Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10 (2004) 1843-1852
25. Del Bufalo D., Ciuffreda L., Trisciuoglio D., Desideri M., Cognetti F., Zupi G., et al. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66 (2006) 5549-5554
26. Raymond E., Alexandre J., Faivre S., Vera K., Materman E., Boni J., et al. Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22 (2004) 2336-2347
27. Hidalgo M., Buckner J.C., Erlichman C., Pollack M.S., Boni J.P., Dukart G., et al. A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12 (2006) 5755-5763
28. Doherty L., Gigas D.C., Kesari S., Drappatz J., Kim R., Zimmerman J., et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67 (2006) 156-158
29. Reardon D.A., Quinn J.A., Vredenburgh J.J., Gururangan S., Friedman A.H., Desjardins A., et al. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res 12 (2006) 860-868
30. Galanis E., Buckner J.C., Maurer M.J., Kreisberg J.I., Ballman K., Boni J., et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 23 (2005) 5294-5304
31. Punt C.J., Boni J., Bruntsch U., Peters M., and Thielert C. Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14 (2003) 931-937
32. Atkins M.B., Hidalgo M., Stadler W.M., Logan T.F., Dutcher J.P., Hudes G.R., et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22 (2004) 909-918
33. Wimmer C.D., Rentsch M., Crispin A., Illner W.D., Arbogast H., Graeb C., et al. The Janus face of immunosuppression - de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 71 (2007) 1271-1278
34. Andrassy J., Graeb C., Rentsch M., Jauch K.W., and Guba M. mTOR inhibition and its effect on cancer in transplantation. Transplantation 80 (2005) S171-S174
35. Campsen J., Zimmerman M.A., Trotter J.F., Wachs M., Bak T., Mandell S., et al. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother 8 (2007) 1275-1282
36. Colombo M.P., and Piconese S. Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer 7 (2007) 880-887
37. Gomez-Camarero J., Salcedo M., Rincon D., Lo Iacono O., Ripoll C., Hernando A., et al. Use of everolimus as a rescue immunosuppressive therapy in liver transplant patients with neoplasms. Transplantation 84 (2007) 786-791